2,692
Views
11
CrossRef citations to date
0
Altmetric
LETTERS TO THE EDITOR: MEDICAL ONCOLOGY

The impact of smoking on the effectiveness of immune checkpoint inhibitors — a systematic review and meta-analysis

, , , , , , , & show all
Pages 96-100 | Received 11 Aug 2019, Accepted 16 Sep 2019, Published online: 25 Sep 2019

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Dahai Hu, Xijiao Pang, Ji Luo, Jiaxin Zhou, Nan Wang, Hui Tang, Liang Wang & Xiaoxu Zhao. (2023) The correlation between the influencing factors and efficacy of immune checkpoint inhibitor therapy: an umbrella meta-analysis of randomized controlled trials. Annals of Medicine 55:1.
Read now

Articles from other publishers (10)

Emily Susannah Mander, Christopher Brian Merrick, Hugh Adam Nicholson, Hannah Kate Lord, Michelle Jane Ferguson & Gillian Smith. (2023) Pembrolizumab monotherapy for non-small cell lung cancer (NSCLC): can patient stratification be improved in the UK Tayside population? A retrospective cohort study. BMJ Open 13:11, pages e076715.
Crossref
Sarah Nasr, Fadi G. Haddad, Joseph Khazen, Joseph Kattan & Viviane Trak-Smayra. (2023) PD-L1 protein expression by Combined Positive Score (CPS) in patients with muscle invasive or advanced urothelial carcinoma: a single institution experience. BMC Cancer 23:1.
Crossref
Anne Lyngholm Sørensen & Ian C Marschner. (2023) Linear mixed models for investigating effect modification in subgroup meta-analysis. Statistical Methods in Medical Research 32:5, pages 994-1009.
Crossref
Lucy K. Corke, Janice J. N. Li, Natasha B. Leighl & Lawson Eng. (2022) Tobacco Use and Response to Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer. Current Oncology 29:9, pages 6260-6276.
Crossref
Marie Bergman, Georgios Fountoukidis, Daniel Smith, Johan Ahlgren, Mats Lambe & Antonios Valachis. (2022) Effect of Smoking on Treatment Efficacy and Toxicity in Patients with Cancer: A Systematic Review and Meta-Analysis. Cancers 14:17, pages 4117.
Crossref
Qian Qin, Tomi Jun, Bo Wang, Vaibhav G. Patel, George Mellgard, Xiaobo Zhong, Mahalya Gogerly-Moragoda, Anish B. Parikh, Amanda Leiter, Emily J. Gallagher, Parissa Alerasool, Philip Garcia, Himanshu Joshi, MBBS, Matthew Galsky, William K. Oh & Che-Kai Tsao. (2022) Clinical factors associated with outcome in solid tumor patients treated with immune-checkpoint inhibitors: a single institution retrospective analysis. Discover Oncology 13:1.
Crossref
Alessio Cortellini, Biagio Ricciuti, Victor R Vaz, Davide Soldato, Joao V Alessi, Filippo G Dall’Olio, Giuseppe L Banna, Sethupathi Muthuramalingam, Samuel Chan, Margarita Majem, Aida Piedra, Giuseppe Lamberti, Elisa Andrini, Alfredo Addeo, Alex Friedlaender, Francesco Facchinetti, Teresa Gorría, Laura Mezquita, Delphine Hoton, Lacroix Valerie, Frank Aboubakar Nana, James Artingstall, Charles Comins, Massimo Di Maio, Andrea Caglio, Judith Cave, Hayley McKenzie, Thomas Newsom-Davis, Joanne S Evans, Marcello Tiseo, Antonio D'Alessio, Claudia A M Fulgenzi, Benjamin Besse, Mark M Awad & David J Pinato. (2022) Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations. Journal for ImmunoTherapy of Cancer 10:2, pages e004374.
Crossref
Wenhua Zhao, Wei Jiang, Huilin Wang, Jianbo He, Cuiyun Su & Qitao Yu. (2021) Impact of Smoking History on Response to Immunotherapy in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Frontiers in Oncology 11.
Crossref
Linzheng Dai, Bo Jin, Tingting Liu, Jun Chen, Guang Li & Jun Dang. (2021) The effect of smoking status on efficacy of immune checkpoint inhibitors in metastatic non-small cell lung cancer: A systematic review and meta-analysis. eClinicalMedicine 38, pages 100990.
Crossref
. (2020) Nivolumab plus Ipilimumab in Non–Small-Cell Lung Cancer. New England Journal of Medicine 382:9, pages 874-875.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.